Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 84

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 84
---
 effects, including inability to or interruption in our ability to operate our business and proceedings
against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with obligations related
to data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited
to, government enforcement actions (e.g., investigations, fines, penalties, audits and inspections, and similar); litigation (including
class-related claims); additional reporting requirements and/or oversight; temporary or permanent bans on all or some processing of personal
data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse
effect on our reputation, business, or financial condition.

The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business model.

Our revenue prospects could
be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry
and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare
availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations
and financial condition.

There have been, and likely
will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability
of healthcare and containing or lowering the cost of healthcare. For more information, see the section of this report titled “Business – Healthcare Laws and Regulations – Healthcare Reform.”

The continuing efforts of
the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of
healthcare and/or impose price controls may adversely affect:

| ● | the demand for our product                    
 candidates, if we obtain regulatory approval; |

| ● | our ability to set a price                
 that we believe is fair for our products; |

<div align='center'>42</div>

| ● | our ability to obtain coverage            
 and reimbursement approval for a product; |

| ● | our ability to generate                        
 revenue and achieve or maintain profitability; |

| ● | the level of taxes that     
 we are required to pay; and |

| ● | the availability of capital. |

Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect
our future profitability.

Our business could be negatively impacted